• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 14, 2013

View Archived Issues

Biotech Diaries: EcoR1 Surveys Investment Options at JPM

The annual J.P. Morgan Healthcare Conference is perhaps more renowned for the dealmaking that occurs on the periphery of San Francisco's Westin St. Francis than for the news and views expressed within the hotel's hallowed halls. Read More

Heard it @JPM in Hallways, Elevators, Street Corners, Suites

SAN FRANCISCO – The J.P. Morgan Healthcare Conference is always bigger than life and full of memorable moments. This year was no different. Read More

Sickle Cells Home to Tumor Blood Vessels

Mostly, the idea behind creating cell lines with diseases is to find ways to fix those diseases. But in the case of sickle cells – red blood cells with an abnormal hemoglobin gene – there may be a twist. Read More

Morphotek's Ovarian Cancer Drug Fails in Phase III Study

Morphotek Inc.'s promising ovarian cancer drug farletuzumab yielded disappointing results in a Phase III trial in ovarian cancer. The study, which combined farletuzumab with carboplatin and taxane in platinum-sensitive epithelial ovarian cancer, did not meet its primary endpoint of progression-free survival (PFS). Read More

Midstage Colorectal Cancer Data Dent ArQule's Shares

Three months after its shares were clobbered on disappointing survival data in non-small-cell lung cancer (NSCLC), ArQule Inc.'s stock sank again, after tivantinib, its MET inhibitor, missed primary and secondary endpoints in a Phase II trial in second-line colorectal cancer (CRC). Read More

Stock Movers

Read More

Other News To Note

• Evotec AG, of Hamburg, Germany, said a compound identified and optimized in a research collaboration with Osaka, Japan-based Ono Pharmaceutical Co. Ltd. was nominated to enter preclinical development, leading to the payment of an undisclosed milestone. Read More

Financings Roundup

• Aegerion Pharmaceuticals Inc., of Cambridge, Mass., priced a public offering of about 2.7 million shares of stock at Thursday's closing price of $26.64 per share, with net proceeds to total about $67.9 million. Read More

Clinic Roundup

• Mesoblast Ltd., of Melbourne, Australia, said its Phase II trial for lumbar spinal fusion met its safety and efficacy endpoints, with results suggesting that NeoFuse, its product comprising allogeneic mesenchymal precursor cells (MPCs), is as effective for interbody lumbar fusion as bone autograft without the need for a second surgical procedure and its attendant morbidity risks. Read More

Pharma: Other News To Note

• Astellas Pharma Inc., of Tokyo, said it received European approval for Betmiga (mirabegron) for treating overactive bladder symptoms in adults. Read More

Pharma: Clinic Roundup

• Novartis AG, of Basel, Switzerland, said data published in The Lancet showed that patients on mTOR inhibitor Afinitor (everolimus) tablets with noncancerous kidney tumors known as renal angiomyolipomas associated with tuberous sclerosis complex experienced a significant reduction in tumor size and the absence of tumor progression. Read More

Bench Press: BioWorld Looks at Translational Medicine

Researchers from the Japanese National Institute of Radiological Sciences have questioned recent findings that induced pluripotent stem cells (iPSCs) may lead to immune rejection. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe